News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Rahul Gosain: HemeSeries, with Naveen Pemmaraju we discuss treatment options and current landscape of Myelofibrosis
A collage photo of Rahul Gosain and Naveen Pemmaraju
May 22, 2024, 03:21

Rahul Gosain: HemeSeries, with Naveen Pemmaraju we discuss treatment options and current landscape of Myelofibrosis

Rahul Gosain, Director of Regional Infusion Services at 

“HemeSeries: with Naveen Pemmaraju we discuss treatment options and current landscape of Myelofibrosis.

Full discussion, Also on the ‘Oncology Brothers’ podcast.”

Additional information.
Proceed to video attached to post.
Source: Rahul Gosain/LinkedIn

 

cancer HemeSeries myelofibrosis Naveen Pemmaraju OncoDaily Oncology Oncology Brothers Rahul Gosain Wilmot Cancer Institute
Insight
Jul 1, 2024, 07:31
Dan Vahdat: Digital-first cancer care for all
Blog
Jul 1, 2024, 06:50
Am I Doing Enough? - Pat Garcia-Gonzalez
Insight
Jul 1, 2024, 06:22
Partnership with Novartis for over 20 years - The Max Foundation
Insight
Jul 1, 2024, 06:11
Conquer Cancer has awarded more than $11 million to physician-scientists at the ASCO Annual Meeting
Drugs
Jul 1, 2024, 06:09
FDA has approved EPKINLY for the treatment of adults with relapsed/refractory follicular lymphoma - Genmab
Insight
Jul 1, 2024, 05:52
The final showcase event of PROTECT-EUROPE and SmartCARE - ECO
Cancer Types
Jul 1, 2024, 05:46
Endometrioid Adenocarcinoma: What patients should know about
Insight
Jul 1, 2024, 05:32
Douglas Flora: AI for mental health and patient support
Blog
Jul 1, 2024, 03:19
Shahrin Ahmed: MED12 is identified as being instrumental in basal-like pancreatic cancer
Blog
Jul 1, 2024, 03:08
Stephen V Liu: Phase III Adjuvant BR.31 study does not meet primary endpoint
Blog
Jul 1, 2024, 02:54
Erman Akkus: Take home messages from Proffered Papers session at ESMOGI24
Blog
Jul 1, 2024, 02:31
Biagio Ricciuti receives a 2024 IASLC YIA to develop new therapies for KRAS amplified NSCLC